Osmind develops measurement tools that gather real-world data to support the design, development, and delivery of new diagnostic and therapeutic solutions such as psychedelic medicines, neuromodulation, digital therapeutics, digital phenotyping, and neuroimaging for treatment-resistant mental health conditions. In addition, Osmind’s electronic health record (EHR) platform allows practices to track measurement-based outcomes of these mental health treatments. The platform includes features like streamlined charting workflows, secure patient engagement tools, and automated outcomes tracking.
Its software solutions also support patient engagement, remote monitoring, and data-driven clinical decision-making. In addition, it provides management tools for mental health practices and an online community for patients with treatment-resistant mental health conditions. The company supports clinicians who provide emerging psychiatric treatments like ketamine therapy, transcranial magnetic stimulation (TMS), and psychedelic medicines.
Osmind is a public benefit company and claims it does not charge patients for its services. Instead, it generates revenue from providers. As of 2022, Osmind reported having collected data on over 2 million patient outcomes through its platform.
Key customers and partnerships
As of 2022, Osmind's software was being used by over 400 clinics across 45 states in the US.
The company has established research partnerships with academic institutions like Stanford University School of Medicine to conduct large-scale studies using real-world clinical data. Osmind has also formed partnerships with companies like Enthea and First Tracks Health to expand insurance coverage for breakthrough mental health treatments among employer-sponsored health plans.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.